サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1429207

DNAメチル化検出技術の世界市場 (2023～2033年)：技術・用途・エンドユーザー・製品タイプ・国別の分析・予測・競合情勢

Global DNA Methylation Detection Technology Market: Focus on Technology, Application, End User, Product Type, Country Level Analysis and Competitive Landscape - Analysis and Forecast, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 109 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
DNAメチル化検出技術の世界市場 (2023～2033年)：技術・用途・エンドユーザー・製品タイプ・国別の分析・予測・競合情勢
出版日: 2024年02月21日
発行: BIS Research
ページ情報: 英文 109 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のDNAメチル化検出技術の市場規模は、2023年の28億米ドルから、予測期間中は15.96%のCAGRで推移し、2033年には123億2,000万米ドルの規模に成長すると予測されています。

同市場の成長は、エピジェネティックバイオマーカーとしてDNAメチル化検出技術の採用が増加していること、学術機関間の共同研究が増加していること、バイオテクノロジーおよび製薬業界で新興企業が増加していることなどに起因しています。

主要市場統計
予測期間 2023-2033年
2023年評価 28億米ドル
2033年予測 123億2,000万米ドル
CAGR 15.96%

世界のDNAメチル化検出技術の市場は、ライフサイクルの成熟成長段階にあると考えられます。研究および臨床の両方の場面でDNAメチル化解析ツールや技術の採用が増加していることに牽引され、市場は急速に拡大しています。さまざまな生物学的プロセスや疾患におけるDNAメチル化の役割に対する理解の深まりと、検出方法や分析プラットフォームの進歩が相まって、市場の成長を後押ししています。さらに、個別化医療と精密診断に対する需要の高まりも市場の拡大をさらに加速させています。市場参入企業が増えるにつれて競合が激化する一方で、技術革新、製品開発、市場浸透の機会は豊富にあります。

製品別では、消耗品の部門が2022年の市場を独占しました。バイサルファイト変換キット、PCR試薬、シーケンシングライブラリーのような消耗品の継続的なニーズが需要を牽引しています。また、技術別では、PCRの部門が2022年の市場で最大のシェアを占めました。PCR法は、その広範な採用、汎用性、信頼性により、世界の市場における優位性を維持すると予想されています。

当レポートでは、世界のDNAメチル化検出技術の市場を調査し、市場概要、市場成長への各種影響因子の分析、技術・特許動向、臨床試験の動向、法規制環境、市場規模の推移・予測、主要国別の詳細分析、主要企業の分析などをまとめています。

目次

エグゼクティブサマリー

第1章 市場

  • 動向：現在および将来の影響評価
    • 主要動向
    • 世界のDNAメチル化検出技術市場におけるゴールドスタンダードとしての亜硫酸水素塩変換
    • 臨床研究用途におけるDNAメチル化検出技術の拡大
  • サプライチェーンの概要
    • バリューチェーン分析
    • マーケットマップ
  • R&Dレビュー
    • 特許出願動向 (国・企業別)
  • 規制状況
  • 主要な世界的出来事の影響分析：COVID-19
  • 市場力学の概要
    • 市場促進要因
    • 市場抑制要因
    • 市場機会

第2章 用途

  • 用途の分類
  • 世界のDNAメチル化検出技術市場 (技術別)
    • ポリメラーゼ連鎖反応 (PCR)
    • マイクロアレイ
    • シーケンス
    • その他
  • 世界のDNAメチル化検出技術市場 (用途別)
    • トランスレーショナル研究
    • 診断
  • 世界のDNAメチル化検出技術市場 (エンドユーザー別)
    • 受託研究機関 (CRO)
    • 研究および学術機関
    • バイオ医薬品・バイオテクノロジー企業
    • その他

第3章 製品

  • 製品の分類
  • 製品概要
  • 製品タイプ
    • 市場概要
  • 世界のDNAメチル化検出技術市場 (製品タイプ別)
    • 消耗品
    • 機器
    • ソフトウェア

第4章 地域

  • 地域概要
  • 促進要因・抑制要因
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域
    • 地域概要
    • 市場成長促進要因
    • 市場課題
    • 国別分析

第5章 市場：競合ベンチマーキングと企業プロファイル

  • 次のフロンティア
  • 地理的評価
    • Agilent Technologies, Inc.
    • Abcam plc.
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Qiagen N.V.
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • Pacific Biosciences of California, Inc.
    • Exact Sciences Corporation
    • Merck KGaA
    • Enzo Life Sciences, Inc.
    • Takara Bio Inc.
    • Revvity, Inc. (PerkinElmer, Inc.)
    • New England Biolabs

第6章 調査手法

図表

List of Figures

  • Figure 1: Global DNA Methylation Detection Technology Market (by Region), $Billion, 2022, 2026, and 2033
  • Figure 2: Global DNA Methylation Detection Technology Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Number of Methylation Analysis Publications, in Thousands, 2002-2020
  • Figure 4: Number of Commercially Available Methylation Tests (by Application Areas)
  • Figure 5: Global DNA Methylation Detection Technology Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 6: Global DNA Methylation Detection Technology Market (by Technology), $Million, 2022, 2026, and 2033
  • Figure 7: Global DNA Methylation Detection Technology Market (by Product Type), $Million, 2022, 2026, and 2033
  • Figure 8: Global DNA Methylation Detection Technology Market, Recent Developments
  • Figure 9: Supply Chain and Risks within the Supply Chain
  • Figure 10: Global DNA Methylation Detection Technology Market (by Country), January 2021-December 2023
  • Figure 11: Global DNA Methylation Detection Technology Market (by Year), January 2021-December 2023
  • Figure 12: Impact of COVID-19 on DNA Methylation Detection Technology
  • Figure 13: Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 14: Advantage of DNA Methylation as Epigenetic Biomarkers
  • Figure 15: Analyzing the Differences: IColocomf vs. FIT and Colonoscopy
  • Figure 16: Evolution in Next-Generation Sequencing (NGS)Techniques for DNA Methylation Analysis, 2005-2021
  • Figure 17: Factors Responsible for Complexity in Data Interpretation
  • Figure 18: Pricing Analysis of Major DNA Methylation Detection Kits and Assays
  • Figure 19: Startups Working in Epigenomics Research
  • Figure 20: Table: Global DNA Methylation Detection Technology Market (by Product Type)
  • Figure 21: U.S. DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 22: Canada DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 23: Germany DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 24: U.K. DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 25: France DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 26: Italy DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 27: Spain DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 28: China DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 29: Japan DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 30: Australia DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 31: South Korea DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 32: Rest-of-Asia-Pacific DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 33: Brazil DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 34: Mexico DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 35: Rest-of-Latin America DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Figure 36: Strategic Initiatives, 2019-2023
  • Figure 37: Share of Strategic Initiatives, 2019-2023
  • Figure 38: Data Triangulation
  • Figure 39: Top-Down and Bottom-Up Approach
  • Figure 40: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global DNA Methylation Detection Technology Market, Opportunities
  • Table 3: Market Share of Key Companies, 2022
  • Table 4: Global DNA Methylation Detection Technology Market, Product Benchmarking
  • Table 5: Examples of Increasing Research in the DNA Methylation Detection Technology Industry
  • Table 6: Key Companies and Technological Advancements, 2019-2023
  • Table 7: Global DNA Methylation Detection Technology Market (by Technology), $Million, 2022-2033
  • Table 8: Global DNA Methylation Detection Technology Market (by Application), $Million, 2022-2033
  • Table 9: Global DNA Methylation Detection Technology Market (by End User), $Million, 2022-2033
  • Table 10: Global DNA Methylation Detection Technology Market (by Product Type), $Million, 2022-2033
  • Table 11: Global DNA Methylation Detection Technology Market (by Consumables), $Million, 2022-2033
  • Table 12: Global DNA Methylation Detection Technology Market (by Region), $Million, 2022-2033
  • Table 13: Rest-of-Europe DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Table 14: India DNA Methylation Detection Technology Market, $Million, 2022-2033
  • Table 15: Company Market Share, 2022
目次
Product Code: BHP1769SA

The Global DNA Methylation Detection Technology Market Expected to Reach $12.32 Billion by 2033

Global DNA Methylation Detection Technology Market Overview

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2023 was $2.80 billion, which is expected to reach $12.32 billion by 2023, growing at a CAGR of 15.96% during the forecast period. This growth can be attributed to the increasing adoption of DNA methylation detection technology as epigenetic biomarkers, increasing collaborations between academic institutions, and rising startups in the biotechnology and pharmaceutical industry. The market includes various consumables, instruments, and software.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$2.80 Billion
2033 Forecast$12.32 Billion
CAGR15.96%

Market Lifecycle Stage

The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle. This stage is characterized by rapid market expansion, driven by the increasing adoption of DNA methylation analysis tools and technologies in both research and clinical settings. The growing understanding of the role of DNA methylation in various biological processes and diseases, coupled with advancements in detection methods and analytical platforms, fuels the market's growth. Additionally, the rising demand for personalized medicine and precision diagnostics further accelerates market expansion. While competition intensifies as more players enter the market, opportunities for innovation, product development, and market penetration abound.

Industry Impact

The global DNA methylation detection technology market has made a profound impact across various industries, revolutionizing healthcare, biotechnology, pharmaceuticals, and research. By enabling the identification of epigenetic biomarkers associated with disease susceptibility, progression, and treatment response, these technologies have advanced precision medicine approaches, allowing for personalized treatment strategies tailored to individual patient's genetic and epigenetic profiles. In drug discovery and development, DNA methylation analysis accelerates the identification of novel drug targets, biomarkers for patient stratification, and predictors of drug response, leading to the development of more effective and safer therapies. Moreover, these technologies are increasingly used in clinical diagnostics for early disease detection, diagnosis, and prognosis, offering high sensitivity and specificity for improved patient outcomes.

The global DNA methylation detection technology market continues to drive transformative advancements across industries, with far-reaching implications for human health and environmental sustainability.

Market Segmentation:

Segmentation 1: by Product

  • Consumables
  • Instruments
  • Software

Consumables to Dominate the Global DNA Methylation Detection Technology Market (by Product)

Based on product, the consumables segment dominated the global DNA methylation detection technology market in FY2022. The recurring need for consumables such as bisulfite conversion kits, PCR reagents, and sequencing libraries drives continuous demand. Secondly, the increasing adoption of high-throughput methods such as next-generation sequencing and microarray analysis requires large quantities of consumables to process samples efficiently. Additionally, as research and clinical applications of DNA methylation analysis expand, the demand for consumables is expected to grow steadily, further solidifying their dominance in the market.

Segmentation 2: by Technology

  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sequencing
  • Other Technologies

PCR to Hold its Dominance in the Global DNA Methylation Detection Technology Market (by Technology)

Based on technology, the PCR segment accounted for the largest share of the global DNA methylation detection technology market in FY2022. Moreover, PCR is expected to maintain its dominance in the global DNA methylation detection technology market by technology due to its widespread adoption, versatility, and reliability. PCR-based methods, such as methylation-specific PCR (MSP) and quantitative real-time PCR (qPCR), offer high sensitivity and specificity for detecting DNA methylation patterns, making them essential tools in epigenetic research and clinical diagnostics.

Segmentation 3: by Application

  • Translational Research
  • Diagnostic Procedure

Diagnostic Procedure to Hold its Dominance in the Global DNA Methylation Detection Technology Market (by Application)

Based on application, diagnostic research accounted for the largest share of the global DNA methylation detection technology market in FY2022, primarily due to clinicians' increasing focus on utilizing DNA methylation analysis for clinical diagnostics. DNA methylation patterns have been extensively studied as potential biomarkers for various diseases, including cancer, neurological disorders, and autoimmune conditions.

Segmentation 4: by End User

  • Contract Research Organization (CRO)
  • Research and Academic Laboratories
  • Biopharmaceutical and Biotech Companies
  • Other End User

Biopharmaceutical and Biotech Companies Segment to Hold its Dominance in the Global DNA Methylation Detection Technology Market (by End User)

Based on end user, the biopharmaceutical and biotech companies segment accounted for the largest share of the global DNA methylation detection technology market in FY2022 due to their extensive use of DNA methylation analysis in drug discovery, development, and personalized medicine applications.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

North America dominated the global DNA methylation detection technology market in 2022. Moreover, Asia-Pacific is expected to register the highest CAGR of 17.79% during the forecast period 2023-2033. The DNA methylation detection technology market in the Asia-Pacific (APAC) region is witnessing significant growth, driven by various factors, some of which include growing investment in epigenetics and biotechnology, a large population base driving demand for diagnostics, and others.

Recent Developments in the Global DNA Methylation Detection Technology Market

  • In August 2023, Pacific Biosciences of California, Inc., and GeneDx initiated a research collaboration with the University of Washington. This partnership focuses on studying the effectiveness of long-read whole genome sequencing in improving diagnostic accuracy in neonatal care.
  • In February 2023, Ultima Genomics, Inc. announced a partnership with New England Biolabs to integrate NEB's NEBNext reagents and library preparation kits into Ultima's sequencing platforms. This collaboration would develop and optimize next-generation sequencing (NGS) processes for DNA, RNA, and methylation sequencing applications.
  • In April 2022, Pacific Biosciences of California, Inc. announced the introduction of the new Revio long-read sequencing system. This system would significantly enhance the use of PacBio's acclaimed HiFi sequencing technology among its users, allowing for more extensive application.
  • In September 2021, Zymo Research Corporation announced that its EZ DNA methylation-lightning kit had been approved for use in the European Union (EU) with the CE IVD Mark. This approval would allow the distribution of the kit within the EU market. The kit's technology, which involves the chemical treatment of DNA with bisulfite, could prove to be essential for various methylation-based diagnostic assays.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

Increasing Adoption of DNA Methylation Detection Technology as Epigenetic Biomarkers: The growing use of DNA methylation detection technology as epigenetic markers significantly drives the global market for DNA methylation detection technology. Its importance stems from its capabilities in the early detection of diseases, tailoring medical treatments to individual needs, and deepening one's understanding of how diseases develop. As research progresses and technology advances, DNA methylation is anticipated to play an increasingly vital role in healthcare, boosting the market's growth and expansion.

Market Restraints:

Complexity in Data Interpretation of DNA Methylation Data: The complexity of data interpretation in DNA methylation detection underscores the need for multidisciplinary collaboration involving molecular biologists, bioinformaticians, clinicians, and data scientists. It also highlights the importance of continuous research and development in the field to refine data analysis methodologies and enhance one's understanding of the epigenetic mechanisms underlying various diseases.

Market Opportunities:

Expansion of DNA Methylation Detection in Emerging Geographies: The expansion of DNA methylation detection technology in emerging geographies is expected to signify its global relevance and potential impact. In these regions, where healthcare infrastructure and resources may be more limited, DNA methylation detection could offer an efficient means of early disease diagnosis.

How can this report add value to an organization?

Workflow/Innovation Strategy: The global DNA methylation detection technology market (by product) has been segmented into detailed segments, including different types of consumables, such as kits and assays, reagents, and enzymes, as well as instruments and software.

Growth/Marketing Strategy: A strategic growth and marketing approach for the DNA methylation detection technology market would involve positioning the company as a leader in innovative solutions that address the evolving needs of researchers, clinicians, and pharmaceutical partners. This would entail leveraging technological advancements to develop cutting-edge products with enhanced sensitivity, specificity, and scalability while also investing in comprehensive customer support, training programs, and collaborative partnerships to foster customer loyalty and drive market penetration. Furthermore, targeted marketing campaigns highlighting the clinical relevance, cost-effectiveness, and competitive advantages of the company's offerings would help to increase brand visibility, attract new customers, and expand market share in this rapidly growing and dynamic industry.

Competitive Strategy: Key players in the global DNA methylation detection technology market have been focusing on innovation, differentiation, and strategic collaborations to gain a competitive edge. By investing in research and development, companies can develop novel detection methods, improve assay sensitivity, and expand application areas. Differentiation through the development of proprietary technologies, customizable solutions, and value-added services can help companies stand out in a crowded market, strengthen market positions, acquire new technologies, and broaden product portfolios.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
  • The geographical distribution of the market revenue has been estimated to be the same as the company's net revenue distribution. All the numbers have been adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR has been calculated from 2023 to 2033.
  • The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of offerings to the global DNA methylation detection technology market have been considered and profiled in the report.
  • In the study, the primary respondent's verification has been considered to finalize the estimated market for the global DNA methylation detection technology market.
  • The latest annual reports of each market player have been taken into consideration for market revenue calculation.
  • Market strategies and developments of key players have been considered for the calculation of sub-segment split.
  • The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company, if stated.

Primary Research

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding of the numbers of the various markets for market type
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, and World Health Organization (WHO)
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their portfolio
  • Gold standard magazines, journals, whitepapers, press releases, and news articles
  • Databases

The key data points taken from the secondary sources include:

  • Segmentations, split-ups, and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions. Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis. These companies provide bisulfite conversion kits, methylation-specific PCR assays, microarray platforms, next-generation sequencing solutions, and bioinformatics software to researchers and clinicians worldwide.

Competition in this market is fierce, driven by continuous technological innovation, expansion of product portfolios, effective marketing strategies, and a focus on regulatory compliance. Additionally, market players vie for market share by establishing strong customer support networks and ensuring high-quality service delivery. As the demand for DNA methylation detection technologies grows, competition intensifies, with companies striving to meet the evolving needs of the research and clinical communities while maintaining a competitive edge in the market.

Some of the prominent companies in this market are:

  • Agilent Technologies, Inc.
  • Abcam plc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Pacific Biosciences of California, Inc.
  • Exact Sciences Corporation
  • Merck KGaA
  • Enzo Life Sciences, Inc.
  • Takara Bio Inc.
  • Revvity, Inc. (PerkinElmer, Inc.)
  • New England Biolabs

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Key Trends
    • 1.1.2 Bisulfite Conversion as a Gold Standard in the Global DNA Methylation Detection Technology Market
    • 1.1.3 Expansion of DNA Methylation Detection Technology in Clinical Research Applications
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
    • 1.2.2 Market Map
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Company)
  • 1.4 Regulatory Landscape
  • 1.5 Impact Analysis for Key Global Events - COVID-19
  • 1.6 Market Dynamics Overview
    • 1.6.1 Market Drivers
      • 1.6.1.1 Increasing Adoption of DNA Methylation Detection Technology as Epigenetic Biomarkers
      • 1.6.1.2 Increasing Research and Development in Genomics and Epigenetics
      • 1.6.1.3 Technological Advancements in Detection Methods
    • 1.6.2 Market Restraints
      • 1.6.2.1 Complexity in Data Interpretation of DNA Methylation Data
      • 1.6.2.2 High Cost of DNA Methylation Detection Instruments and Various Kits and Assays
    • 1.6.3 Market Opportunities
      • 1.6.3.1 DNA Methylation Detection Technology as an Early Disease Diagnostic Tool
      • 1.6.3.2 Expansion of DNA Methylation Detection in Emerging Geographies

2 Application

  • 2.1 Application Segmentation
  • 2.2 Global DNA Methylation Detection Technology Market (by Technology)
    • 2.2.1 Polymerase Chain Reaction (PCR)
    • 2.2.2 Microarray
    • 2.2.3 Sequencing
    • 2.2.4 Other Technologies
  • 2.3 Global DNA Methylation Detection Technology Market (by Application)
    • 2.3.1 Translational Research
    • 2.3.2 Diagnostic Procedures
  • 2.4 Global DNA Methylation Detection Technology Market (by End User)
    • 2.4.1 Contract Research Organization (CRO)
    • 2.4.2 Research and Academic Institutions
    • 2.4.3 Biopharmaceutical and Biotech Companies
    • 2.4.4 Other End Users

3 Products

  • 3.1 Product Segmentation
  • 3.2 Product Summary
  • 3.3 Product Type
    • 3.3.1 Market Overview
      • 3.3.1.1 Analyst View
  • 3.4 Global DNA Methylation Detection Technology Market (by Product Type)
    • 3.4.1 Consumables
      • 3.4.1.1 Kits and Assays
      • 3.4.1.2 Reagents
      • 3.4.1.3 Enzymes
    • 3.4.2 Instruments
    • 3.4.3 Software

4 Regions

  • 4.1 Regional Summary
  • 4.2 Drivers and Restraints
  • 4.3 North America
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
    • 4.3.4 U.S.
    • 4.3.5 Canada
  • 4.4 Europe
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
    • 4.4.4 Germany
    • 4.4.5 U.K.
    • 4.4.6 France
    • 4.4.7 Italy
    • 4.4.8 Spain
    • 4.4.9 Rest-of-Europe
  • 4.5 Asia-Pacific
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
    • 4.5.4 China
    • 4.5.5 Japan
    • 4.5.6 India
    • 4.5.7 Australia
    • 4.5.8 South Korea
    • 4.5.9 Rest-of-Asia-Pacific
  • 4.6 Latin America
    • 4.6.1 Regional Overview
    • 4.6.2 Driving Factors for Market Growth
    • 4.6.3 Factors Challenging the Market
    • 4.6.4 Brazil
    • 4.6.5 Mexico
    • 4.6.6 Rest-of-Latin America
  • 4.7 Rest-of-the-World
    • 4.7.1 Regional Overview
    • 4.7.2 Driving Factors for Market Growth
    • 4.7.3 Factors Challenging the Market

5 Markets - Competitive Benchmarking & Company Profiles

  • 5.1 Next Frontiers
  • 5.2 Geographic Assessment
    • 5.2.1 Agilent Technologies, Inc.
      • 5.2.1.1 Overview
      • 5.2.1.2 Top Products/Product Portfolio
      • 5.2.1.3 Top Competitors
      • 5.2.1.4 Key Personnel
      • 5.2.1.5 Analyst View
    • 5.2.2 Abcam plc.
      • 5.2.2.1 Overview
      • 5.2.2.2 Top Products/Product Portfolio
      • 5.2.2.3 Top Competitors
      • 5.2.2.4 Key Personnel
      • 5.2.2.5 Analyst View
    • 5.2.3 Bio-Rad Laboratories, Inc.
      • 5.2.3.1 Overview
      • 5.2.3.2 Top Products/Product Portfolio
      • 5.2.3.3 Top Competitors
      • 5.2.3.4 Key Personnel
      • 5.2.3.5 Analyst View
    • 5.2.4 Illumina, Inc.
      • 5.2.4.1 Overview
      • 5.2.4.2 Top Products/Product Portfolio
      • 5.2.4.3 Top Competitors
      • 5.2.4.4 Key Personnel
      • 5.2.4.5 Analyst View
    • 5.2.5 Qiagen N.V.
      • 5.2.5.1 Overview
      • 5.2.5.2 Top Products/Product Portfolio
      • 5.2.5.3 Top Competitors
      • 5.2.5.4 Key Personnel
      • 5.2.5.5 Analyst View
    • 5.2.6 Thermo Fisher Scientific, Inc.
      • 5.2.6.1 Overview
      • 5.2.6.2 Top Products/Product Portfolio
      • 5.2.6.3 Top Competitors
      • 5.2.6.4 Key Personnel
      • 5.2.6.5 Analyst View
    • 5.2.7 F. Hoffmann-La Roche Ltd.
      • 5.2.7.1 Overview
      • 5.2.7.2 Top Products/Product Portfolio
      • 5.2.7.3 Top Competitors
      • 5.2.7.4 Key Personnel
      • 5.2.7.5 Analyst View
    • 5.2.8 Hologic, Inc.
      • 5.2.8.1 Overview
      • 5.2.8.2 Top Products/Product Portfolio
      • 5.2.8.3 Top Competitors
      • 5.2.8.4 Key Personnel
      • 5.2.8.5 Analyst View
    • 5.2.9 Pacific Biosciences of California, Inc.
      • 5.2.9.1 Overview
      • 5.2.9.2 Top Products/Product Portfolio
      • 5.2.9.3 Top Competitors
      • 5.2.9.4 Key Personnel
      • 5.2.9.5 Analyst View
    • 5.2.10 Exact Sciences Corporation
      • 5.2.10.1 Overview
      • 5.2.10.2 Top Products/Product Portfolio
      • 5.2.10.3 Top Competitors
      • 5.2.10.4 Key Personnel
      • 5.2.10.5 Analyst View
    • 5.2.11 Merck KGaA
      • 5.2.11.1 Overview
      • 5.2.11.2 Top Products/Product Portfolio
      • 5.2.11.3 Top Competitors
      • 5.2.11.4 Key Personnel
      • 5.2.11.5 Analyst View
    • 5.2.12 Enzo Life Sciences, Inc.
      • 5.2.12.1 Overview
      • 5.2.12.2 Top Products/Product Portfolio
      • 5.2.12.3 Top Competitors
      • 5.2.12.4 Key Personnel
      • 5.2.12.5 Analyst View
    • 5.2.13 Takara Bio Inc.
      • 5.2.13.1 Overview
      • 5.2.13.2 Top Products/Product Portfolio
      • 5.2.13.3 Top Competitors
      • 5.2.13.4 Key Personnel
      • 5.2.13.5 Analyst View
    • 5.2.14 Revvity, Inc. (PerkinElmer, Inc.)
      • 5.2.14.1 Overview
      • 5.2.14.2 Top Products/Product Portfolio
      • 5.2.14.3 Top Competitors
      • 5.2.14.4 Key Personnel
      • 5.2.14.5 Analyst View
    • 5.2.15 New England Biolabs
      • 5.2.15.1 Overview
      • 5.2.15.2 Top Products/Product Portfolio
      • 5.2.15.3 Top Competitors
      • 5.2.15.4 Key Personnel
      • 5.2.15.5 Analyst View

6 Research Methodology

  • 6.1 Data Sources
    • 6.1.1 Primary Data Sources
    • 6.1.2 Secondary Data Sources
    • 6.1.3 Data Triangulation
  • 6.2 Market Estimation and Forecast